Refine by
Protective Immunity Articles & Analysis: Older
20 news found
This unique auto-adjuvanted antigen presentation platform has successfully demonstrated the capacity to elicit protective/neutralizing immune responses against allergens and ...
A recently completed Phase 2 clinical trial in COVID-19 prevention demonstrated 96% cellular immune protection efficiency to SARS-CoV-2 with the fewest and lowest adverse events of any published COVID-19 ...
GMT was measured across three age groups and demonstrated strong immune response after the second dose. There were no serious adverse events such as myocarditis, pericarditis, or blood clots, reported in any of the three age groups. This immunobridging trial was intended to determine if COVAXIN™ generates the same protective immunity in ...
Millions of years of evolution have taught our immune system how to protect against pathogens. Angany brings a novel generation of allergy immunotherapy where allergens are administered under the form of pseudo-pathogens to elicit a protective immune response. ...
The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. ...
The second manuscript has been published in “Vaccine” and provides important data validating the potential of V-306 to be administered ‘epicutaneously’ via skin patch delivery, as a method to boost protective immunity to RSV following initial intramuscular injection. Following administration of V-306, the immune response ...
Probiotics are beneficial forms of gut bacteria that help stimulate the natural digestive juices and enzymes that keep our digestive organs functioning properly. Microalgae are probiotic foods that have been shown to increase the amount of both Lactobacillus and bifidobacteria in the digestive tract. In addition to detoxify our body, microalgae stimulate the immune system. Must ...
Novavax' recombinant protein vaccine candidate, NVX-CoV2373, is one of four COVID-19 vaccines that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. "Novavax' addition to this important study reflects the urgency of finding innovative ways to ...
ByNovavax
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
Evaxion’s EDEN AI platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. It has been designed to rapidly identify those antigens that will trigger a robust protective immune response against almost any bacterial infectious ...
Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal immunity by inhibition of eATP signalling Enhancement of immune checkpoint blockade by eATP interfering biotherapeutics “We were ...
About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal ...
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global ...
Food and Drug Administration (FDA) for the development of MV-014-210, a live attenuated vaccine (LAV) candidate to induce immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. ...
About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal ...
” The abbreviation MV is directly related to the two patented microorganisms ApyraMed® and ApyraVax® About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism ...
An important, emerging question is whether individuals who have antibodies to the virus that causes COVID-19 have acquired protective immunity.? To answer this question, tests which can accurately measure the levels of IgG and IgM antibodies quantitatively in blood samples are needed.? The test that we are developing will enable such quantitation and may ...
Considerable efforts over the last few years to develop this innovative synthetic viruslike particle (SVLP) platform have resulted in a vaccine candidate that has the potential to protect vulnerable patients from the serious morbidity and mortality associated with RSV infection. ...
A new peer-reviewed study reveals that the vast majority of U.S. infants may be suffering from a substantial deficiency in an important bacterium key to breast milk utilization and immune system development, as well as protection against gut pathogens linked to common newborn conditions such as colic and diaper rash. ...
Scientists have developed a vaccine strain that has tested 100 percent effective in protecting chickens from bird flu and testing is underway to see if it also protects turkeys, U.S. ...